

FGF-basic

Catalog # PVGS1686

Product Information

Primary Accession XP 035600424.1

Species Salmon

Sequence Full length

Purity ≥ 95% as analyzed by SDS-PAGE

Endotoxin Level

Biological Activity $EC_{50 50}$, the calculated specific activity is approximately > 1.0 × 10⁶ IU/mg. It is

recommended to experimentally determine the optimal concentration for

each specific application by performing a dose response assay.

Expression System E. coli

Theoretical Molecular Weight 17.1 kDa

Formulation Lyophilized from a 0.2 Im filtered solution in 7.8 mM Na₂HPO₄, 1.5 mM

KH₂PO₄, 2.7 mM KCl, 500 mM NaCl.

Reconstitution Before opening, centrifuge the vial briefly to bring the contents to the bottom.

Reconstitute the lyophilized powder in PBS up to 100 [g/ml.

Storage & Stability Upon receiving, the lyophilized product remains stable for up to 6 months at

lower than -70 °C. Upon reconstitution, the product is stable for up to 1 week at 4 °C or up to 3 months at -20 °C. Avoid repeated freeze-thaw cycles by making single-use aliquots before the solution is storage at -20 °C.

Additional Information

Target Background Fibroblast Growth Factor-basic (FGF-basic), also known as FGF-2, is a

pleiotropic cytokine and one of the prototypic members of the

heparin-binding FGF family. Like other FGF family members, FGF-basic has the

β trefoil structure. In vivo, FGF-basic is produced by a variety of cells, including cardiomyocytes, fibroblasts, and vascular cells. FGF-basic regulates a variety of processes including cell proliferation, differentiation, survival, adhesion, motility, apoptosis, limb formation and wound healing. FGF-basic

can be tumorigenic due to its role in angiogenesis and blood vessel remodeling. The angiogenic effects of FGF-basic can produce beneficial

cardioprotection during acute heart injury.

Protein Information

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.